Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study
Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne ® ) for endometriosis was conducted to assess the safety and effectiveness of...
Saved in:
| Published in | Reproductive sciences (Thousand Oaks, Calif.) Vol. 27; no. 3; pp. 905 - 915 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.03.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1933-7191 1933-7205 1933-7205 |
| DOI | 10.1007/s43032-019-00094-5 |
Cover
| Abstract | Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne
®
) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were “abnormal uterine bleeding” 4.14% (129/3113), “increased weight” 2.57% (80/3113), and “headache” 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was −28.19 ± 28.39 mm (
P
value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis. |
|---|---|
| AbstractList | Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne
) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were "abnormal uterine bleeding" 4.14% (129/3113), "increased weight" 2.57% (80/3113), and "headache" 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was -28.19 ± 28.39 mm (P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis. Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne®) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were "abnormal uterine bleeding" 4.14% (129/3113), "increased weight" 2.57% (80/3113), and "headache" 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was -28.19 ± 28.39 mm (P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis.Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne®) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were "abnormal uterine bleeding" 4.14% (129/3113), "increased weight" 2.57% (80/3113), and "headache" 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was -28.19 ± 28.39 mm (P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis. Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne ® ) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were “abnormal uterine bleeding” 4.14% (129/3113), “increased weight” 2.57% (80/3113), and “headache” 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was −28.19 ± 28.39 mm ( P value < 0.0001). This large cohort study confirms, in routine clinical practice, that DNG is safe and effective for treatment of endometriosis. |
| Author | Cho, BaikSeol Cho, Chi-Heum Park, Jonghoon Park, Sung Ho Jeong, Kyungah Kim, Yun Sook Kwon, Yong-Soon Kim, Tae-Hee Roh, Ju-Won Kim, Sung Hoon |
| Author_xml | – sequence: 1 givenname: BaikSeol surname: Cho fullname: Cho, BaikSeol organization: Medical Affairs Women’s Healthcare, Bayer Korea Ltd. Pharmaceutical – sequence: 2 givenname: Ju-Won surname: Roh fullname: Roh, Ju-Won organization: Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital – sequence: 3 givenname: Jonghoon surname: Park fullname: Park, Jonghoon organization: Department of Obstetrics and Gynecology, Ilsin Christian Hospital, Department of Obstetrics and Gynecology, Bonseng Memorial Hospital – sequence: 4 givenname: Kyungah surname: Jeong fullname: Jeong, Kyungah organization: Department of Obstetrics and Gynecology, College of Medicine, Ewha Womans University Mokdong Hospital – sequence: 5 givenname: Tae-Hee surname: Kim fullname: Kim, Tae-Hee organization: Department of Obstetrics and Gynecology, Soonchunhyang University Bucheon Hospital – sequence: 6 givenname: Yun Sook surname: Kim fullname: Kim, Yun Sook organization: Soonchunhyang University College of Medicine, Soonchunhyang University Cheonan Hospital – sequence: 7 givenname: Yong-Soon surname: Kwon fullname: Kwon, Yong-Soon organization: Department of Obstetrics and Gynecology, Ulsan University Hospital, Ulsan University College of Medicine, Department of Obstetrics and Gynecology, Eulji University, Nowon Eulji Medical Center – sequence: 8 givenname: Chi-Heum surname: Cho fullname: Cho, Chi-Heum organization: Obstetrics and Gynecology, School of Medicine, Keimyung University – sequence: 9 givenname: Sung Ho surname: Park fullname: Park, Sung Ho organization: Department of Obstetrics and Gynecology, Kangnam Sacred Heart Hospital, Hallym University – sequence: 10 givenname: Sung Hoon surname: Kim fullname: Kim, Sung Hoon email: kimsung@amc.seoul.kr organization: Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32052358$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctuFDEQRS0URB7wAyyQl8miofzqB7tomASkkRIpga3lcVcPjqbtwXYjzU_lI_gyHDqzYZFVlVTnXqnuPSVHPngk5D2Djwyg-ZSkAMErYF0FAJ2s1CtywjohqoaDOjrsrGPH5DSlBwAlO96-Icei3LlQ7QmJd2bAvKfG93Q5DGiz-40eU6JhoF8c-rDBlOn5D5eM9_jn8YIOIdL7iCaP6PMTtvR9GDFHF5JLn-klXZm4QXobQ9rNhnQRfoaY6V2e-v1b8now24TvnucZ-X61vF98rVY3198Wl6vKCtnkSmErwFhmEHreqnULrDbGyLpTa2uFaizra2gbLteghDSNtUNdcw4dGCYQxRk5n313Mfyayhd6dMnidms8hinpEoBshFKdLOiHZ3Raj9jrXXSjiXt9yKkA7QzY8lSKOGjrssku-ByN22oG-qkSPVeiSyX6XyVaFSn_T3pwf1EkZlEqsN9g1A9hir7E9ZLqL8MBnlY |
| CitedBy_id | crossref_primary_10_1080_09513590_2021_1892632 crossref_primary_10_1080_09513590_2024_2336121 crossref_primary_10_1080_09513590_2022_2098948 crossref_primary_10_1016_j_ejphar_2025_177440 crossref_primary_10_3390_biomedicines10112992 crossref_primary_10_1007_s10304_023_00524_3 crossref_primary_10_1007_s11154_021_09666_w crossref_primary_10_3389_fphar_2024_1373582 crossref_primary_10_1002_cpdd_1215 crossref_primary_10_1002_rmb2_12588 crossref_primary_10_3389_fsurg_2022_992490 crossref_primary_10_1002_ijgo_15142 crossref_primary_10_1186_s12905_022_02122_0 crossref_primary_10_1186_s40360_024_00767_1 crossref_primary_10_23736_S2724_5276_21_06375_8 crossref_primary_10_1016_j_ejogrb_2024_03_032 crossref_primary_10_3390_biomedicines10123245 crossref_primary_10_1016_j_sagf_2021_03_005 crossref_primary_10_12998_wjcc_v12_i21_4601 crossref_primary_10_1007_s00404_023_07271_7 |
| Cites_doi | 10.1016/j.ijgo.2009.08.020 10.1093/humrep/det457 10.1016/S0002-9343(99)80067-9 10.1080/14656566.2017.1414182 10.1016/S1701-2163(16)34589-3 10.1038/s41572-018-0008-5 10.1097/GRF.0000000000000291 10.1093/humrep/dep469 10.1016/j.jmig.2015.04.017 10.1007/s13669-017-0187-1 10.1111/1471-0528.14711 10.1159/000452660 10.2147/IJWH.S77202 10.1186/1477-7525-8-138 10.1016/j.fertnstert.2006.11.051 10.1093/humupd/dmp007 10.3988/jcn.2012.8.3.204 10.5653/cerm.2016.43.4.215 10.1093/humrep/dei135 10.1016/j.steroids.2007.10.003 10.1016/j.fertnstert.2004.03.046 10.1016/j.ejogrb.2010.04.002 10.1212/WNL.0000000000002798 10.1089/jwh.2017.6399 10.1111/j.1468-2982.2007.01288.x 10.1016/j.fertnstert.2007.03.069 10.1089/jwh.2018.7084 10.1055/s-0031-1287662 10.1016/j.jsps.2013.02.003 10.1016/S0015-0282(97)81391-X 10.1186/s40413-017-0176-x 10.1111/j.1471-0528.2010.02774.x 10.1111/j.1471-0528.2008.01878.x 10.1007/s00404-011-1941-7 10.1093/humupd/dmt027 10.3389/fsurg.2014.00024 |
| ContentType | Journal Article |
| Copyright | Society for Reproductive Investigation 2019 |
| Copyright_xml | – notice: Society for Reproductive Investigation 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1007/s43032-019-00094-5 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1933-7205 |
| EndPage | 915 |
| ExternalDocumentID | 32052358 10_1007_s43032_019_00094_5 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -MK -TM 01A 0R~ 123 29P 2JY 4.4 406 53G 5VS AACDK AADTT AAHNG AAJBT AAJPV AAQDB AARDL AASML AATNV AAUYE ABAKF ABAWP ABCCA ABECU ABEIX ABFWQ ABJNI ABMQK ABQXT ABTEG ABTKH ABTMW ACAOD ACDSZ ACDTI ACDXX ACGFS ACHSB ACMLO ACOKC ACRPL ACSBE ACTQU ACUIR ACZOJ ADBBV ADKNI ADNMO ADTPH ADYCS ADYFF ADZZY AEFQL AEMSY AENEX AEQLS AERKM AESKC AEUHG AEUIJ AEWDL AFBBN AFEET AFQWF AFWMB AGMZJ AGQEE AHHFK AIGIU AILAN AJZVZ ALMA_UNASSIGNED_HOLDINGS AMXSW AMYLF ARTOV AUTPY AYAKG AZFZN B8M BGNMA CAG COF CS3 DD0 DPUIP DU5 DV7 EBLON EBS EJD EMOBN F5P FEDTE FIGPU FNLPD GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HVGLF HZ~ IKXTQ IWAJR J8X JZLTJ K.F KOV LLZTM M4V M4Y N9A NPVJJ NQJWS NU0 O9- P.B PT4 RIG ROL RSV S01 SAUOL SCLPG SCNPE SDE SFC SJYHP SNE SNPRN SOHCF SOJ SQCSI SRMVM SSLCW TSG UOJIU UTJUX ZMTXR AAYXX ABBRH ABDBE ABFSG ACSTC ADEBD ADSTG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION CGR CUY CVF ECM EIF NPM 7X8 ABRTQ M41 |
| ID | FETCH-LOGICAL-c347t-5e830ac1ae0d285b8016aaa4695bcc357c1d608724b0534a7ccf6622090a13ee3 |
| ISSN | 1933-7191 1933-7205 |
| IngestDate | Fri Sep 05 13:31:31 EDT 2025 Wed Feb 19 02:30:01 EST 2025 Tue Jul 01 03:19:33 EDT 2025 Thu Apr 24 23:08:22 EDT 2025 Fri Feb 21 02:35:52 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Endometriosis Effectiveness Safety Cohort study Dienogest |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c347t-5e830ac1ae0d285b8016aaa4695bcc357c1d608724b0534a7ccf6622090a13ee3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 32052358 |
| PQID | 2354735594 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2354735594 pubmed_primary_32052358 crossref_citationtrail_10_1007_s43032_019_00094_5 crossref_primary_10_1007_s43032_019_00094_5 springer_journals_10_1007_s43032_019_00094_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200300 2020-03-00 20200301 |
| PublicationDateYYYYMMDD | 2020-03-01 |
| PublicationDate_xml | – month: 3 year: 2020 text: 20200300 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: United States |
| PublicationTitle | Reproductive sciences (Thousand Oaks, Calif.) |
| PublicationTitleAbbrev | Reprod. Sci |
| PublicationTitleAlternate | Reprod Sci |
| PublicationYear | 2020 |
| Publisher | Springer International Publishing |
| Publisher_xml | – name: Springer International Publishing |
| References | Fuldeore, Soliman (CR10) 2017; 82 Kennedy, Bergqvist, Chapron, D'Hooghe, Dunselman, Greb, Hummelshoj, Prentice, Saridogan (CR1) 2005; 20 Fraser, Critchley, Broder, Munro (CR31) 2011; 29 Prentice, Deary, Bland (CR19) 2000; 2 Pavlović, Allshouse, Santoro, Crawford, Thurston, Neal-Perry, Lipton, Derby (CR40) 2016; 87 Guy (CR34) 1976 CR14 CR35 Zanelotti, Decherney (CR13) 2017; 60 Yu, Zhang, Li (CR29) 2019; 28 Chudnoff, Nichols, Levie (CR33) 2015; 22 Kim, Chu, Lee, Kim, Chung, Lee (CR37) 2012; 8 Oettel, Carol, Elger (CR21) 1995; 31 Petraglia, Hornung, Seitz, Faustmann, Gerlinger, Luisi, Lazzeri, Strowitzki (CR27) 2012; 285 Alomar (CR43) 2014; 22 Parasar, Ozcan, Terry (CR11) 2017; 6 Sinaii, Cleary, Younes, Ballweg, Stratton (CR3) 2007; 87 Guo (CR17) 2009; 15 Strowitzki, Faustmann, Gerlinger, Schumacher, Ahlers, Seitz (CR23) 2015; 7 Strowitzki, Marr, Gerlinger, Faustmann, Seitz (CR26) 2010; 25 Prentice, Deary, Goldbeck-Wood, Farquhar, Smith (CR20) 2007; 2 Stovner, Hagen, Jensen (CR38) 2007; 27 Kondo, Bourdel, Tamburro, Cavoli, Jardon, Rabischong, Botchorishvili, Pouly, Mage, Canis (CR18) 2011; 118 Leyland, Casper, Laberge, Singh (CR15) 2010; 32 Untersmayr, Jensen, Walch (CR44) 2017; 10 Allais, Chiarle, Sinigaglia, Benedetto (CR39) 2018; 19 Park, Kim, Chae, Kim, Kang (CR42) 2016; 43 Imthurn, Marions, Möhner, Becker, Faustmann, Heinemann (CR36) 2018; 110 Abbott, Hawe, Hunter, Holmes, Finn, Garry (CR16) 2004; 82 Sasagawa, Shimizu, Kami, Takeuchi, Mita, Imada, Kato, Mizuguchi (CR22) 2008; 73 Eisenberg, Weil, Chodick, Shalev (CR12) 2018; 125 CR9 Culley, Law, Hudson, Denny, Mitchell, Baumgarten, Raine-Fenning (CR7) 2013; 19 Lang, Yu, Zhang (CR28) 2018; 27 Mounsey, Wilgus, Slawson (CR2) 2006; 74 Zondervan, Becker, Koga, Missmer, Taylor, Viganò (CR4) 2018; 4 (CR30) 1997; 67 Ballard, Seaman, de Vries, Wright (CR6) 2008; 115 Dunselman, Vermeulen, Becker, Calhaz-Jorge, D'Hooghe, de Bie, Heikinheimo, Horne, Kiesel, Nap, Prentice, Saridogan, Soriano, Nelen (CR8) 2014; 29 Köhler, Faustmann, Gerlinger, Seitz, Mueck (CR24) 2010; 108 Darney (CR41) 1995; 98 Sinaii, Plumb, Cotton, Lambert, Kennedy, Zondervan, Stratton (CR5) 2008; 89 Strowitzki, Faustmann, Gerlinger, Seitz (CR25) 2010; 151 Gerlinger, Schumacher, Faustmann, Colligs, Schmitz, Seitz (CR32) 2010; 8 GA Dunselman (94_CR8) 2014; 29 G Köhler (94_CR24) 2010; 108 T Strowitzki (94_CR25) 2010; 151 S Kennedy (94_CR1) 2005; 20 KD Ballard (94_CR6) 2008; 115 J Abbott (94_CR16) 2004; 82 A Prentice (94_CR20) 2007; 2 American Society For Reproductive Medicine (94_CR30) 1997; 67 SY Park (94_CR42) 2016; 43 W Guy (94_CR34) 1976 F Petraglia (94_CR27) 2012; 285 E Untersmayr (94_CR44) 2017; 10 N Sinaii (94_CR5) 2008; 89 94_CR9 KT Zondervan (94_CR4) 2018; 4 IS Fraser (94_CR31) 2011; 29 PD Darney (94_CR41) 1995; 98 T Strowitzki (94_CR26) 2010; 25 JM Pavlović (94_CR40) 2016; 87 C Gerlinger (94_CR32) 2010; 8 LJ Stovner (94_CR38) 2007; 27 M Oettel (94_CR21) 1995; 31 AL Mounsey (94_CR2) 2006; 74 N Leyland (94_CR15) 2010; 32 SG Chudnoff (94_CR33) 2015; 22 L Culley (94_CR7) 2013; 19 MJ Alomar (94_CR43) 2014; 22 MJ Fuldeore (94_CR10) 2017; 82 94_CR35 J Lang (94_CR28) 2018; 27 N Sinaii (94_CR3) 2007; 87 94_CR14 B Imthurn (94_CR36) 2018; 110 A Zanelotti (94_CR13) 2017; 60 W Kondo (94_CR18) 2011; 118 VH Eisenberg (94_CR12) 2018; 125 T Strowitzki (94_CR23) 2015; 7 Q Yu (94_CR29) 2019; 28 P Parasar (94_CR11) 2017; 6 BK Kim (94_CR37) 2012; 8 SW Guo (94_CR17) 2009; 15 S Sasagawa (94_CR22) 2008; 73 A Prentice (94_CR19) 2000; 2 G Allais (94_CR39) 2018; 19 |
| References_xml | – volume: 2 start-page: CD000346 year: 2007 ident: CR20 article-title: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis publication-title: Cochrane Database Syst Rev – volume: 108 start-page: 21 issue: 1 year: 2010 end-page: 25 ident: CR24 article-title: A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2009.08.020 – volume: 29 start-page: 400 issue: 3 year: 2014 end-page: 412 ident: CR8 article-title: ESHRE guideline: management of women with endometriosis publication-title: Hum Reprod doi: 10.1093/humrep/det457 – volume: 98 start-page: 104S issue: 1A year: 1995 end-page: 110S ident: CR41 article-title: The androgenicity of progestins publication-title: Am J Med doi: 10.1016/S0002-9343(99)80067-9 – volume: 19 start-page: 123 issue: 2 year: 2018 end-page: 136 ident: CR39 article-title: Menstrual migraine: a review of current and developing pharmacotherapies for women publication-title: Expert Opin Pharmacother doi: 10.1080/14656566.2017.1414182 – ident: CR14 – volume: 32 start-page: S1 issue: 7 Suppl 2 year: 2010 end-page: 32 ident: CR15 article-title: Endometriosis: diagnosis and management publication-title: J Obstet Gynaecol Can doi: 10.1016/S1701-2163(16)34589-3 – volume: 4 start-page: 9 issue: 1 year: 2018 ident: CR4 article-title: Endometriosis publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-018-0008-5 – volume: 60 start-page: 477 issue: 3 year: 2017 end-page: 484 ident: CR13 article-title: Surgery and endometriosis publication-title: Clin Obstet Gynecol doi: 10.1097/GRF.0000000000000291 – volume: 2 start-page: CD002122 year: 2000 ident: CR19 article-title: Progestogens and anti-progestogens for pain associated with endometriosis publication-title: Cochrane Database Syst Rev – volume: 25 start-page: 633 issue: 3 year: 2010 end-page: 641 ident: CR26 article-title: Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial publication-title: Hum Reprod doi: 10.1093/humrep/dep469 – volume: 22 start-page: 951 issue: 6 year: 2015 end-page: 960 ident: CR33 article-title: Hysteroscopic essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study publication-title: J Minim Invasive Gynecol doi: 10.1016/j.jmig.2015.04.017 – volume: 6 start-page: 34 issue: 1 year: 2017 end-page: 41 ident: CR11 article-title: Endometriosis: epidemiology, diagnosis and clinical management publication-title: Curr Obstet Gynecol Rep doi: 10.1007/s13669-017-0187-1 – ident: CR35 – volume: 125 start-page: 55 issue: 1 year: 2018 end-page: 62 ident: CR12 article-title: Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members publication-title: BJOG. doi: 10.1111/1471-0528.14711 – volume: 74 start-page: 594 issue: 4 year: 2006 end-page: 600 ident: CR2 article-title: Diagnosis and management of endometriosis publication-title: Am Fam Physician – volume: 82 start-page: 453 issue: 5 year: 2017 end-page: 461 ident: CR10 article-title: Prevalence and symptomatic burden of diagnosed endometriosis in the United States: National Estimates from a cross-sectional survey of 59,411 women publication-title: Gynecol Obstet Investig doi: 10.1159/000452660 – volume: 31 start-page: 517 year: 1995 end-page: 536 ident: CR21 article-title: A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view publication-title: Drugs Today – volume: 7 start-page: 393 year: 2015 end-page: 401 ident: CR23 article-title: Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program publication-title: Int J Women's Health doi: 10.2147/IJWH.S77202 – volume: 8 start-page: 138 year: 2010 ident: CR32 article-title: Defining a minimal clinically important difference for endometriosis associated pelvic pain measured on a visual analog scale: analysis of two placebo controlled, randomized trials publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-8-138 – start-page: 218 year: 1976 end-page: 222 ident: CR34 publication-title: ECDEU Assessment Manual for Psychopharmacology (028 clinical global impressions [CGI]) – volume: 87 start-page: 1277 issue: 6 year: 2007 end-page: 1286 ident: CR3 article-title: Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2006.11.051 – volume: 15 start-page: 441 issue: 4 year: 2009 end-page: 461 ident: CR17 article-title: Recurrence of endometriosis and its control publication-title: Hum Reprod Update doi: 10.1093/humupd/dmp007 – volume: 8 start-page: 204 issue: 3 year: 2012 end-page: 211 ident: CR37 article-title: Prevalence and impact of migraine and tension-type headache in Korea publication-title: J Clin Neurol doi: 10.3988/jcn.2012.8.3.204 – volume: 43 start-page: 215 issue: 4 year: 2016 end-page: 220 ident: CR42 article-title: Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months publication-title: Clin Exp Reprod Med doi: 10.5653/cerm.2016.43.4.215 – volume: 20 start-page: 2698 issue: 10 year: 2005 end-page: 2704 ident: CR1 article-title: ESHRE guideline for the diagnosis and treatment of endometriosis publication-title: Hum Reprod doi: 10.1093/humrep/dei135 – volume: 73 start-page: 222 issue: 2 year: 2008 end-page: 231 ident: CR22 article-title: Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile publication-title: Steroids. doi: 10.1016/j.steroids.2007.10.003 – volume: 82 start-page: 878 issue: 4 year: 2004 end-page: 884 ident: CR16 article-title: Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2004.03.046 – volume: 151 start-page: 193 issue: 2 year: 2010 end-page: 198 ident: CR25 article-title: Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2010.04.002 – volume: 87 start-page: 49 issue: 1 year: 2016 end-page: 56 ident: CR40 article-title: Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles publication-title: Neurology. doi: 10.1212/WNL.0000000000002798 – volume: 27 start-page: 148 issue: 2 year: 2018 end-page: 155 ident: CR28 article-title: Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study publication-title: J Women's Health (Larchmt) doi: 10.1089/jwh.2017.6399 – volume: 110 start-page: e392 issue: 4 year: 2018 ident: CR36 article-title: Baseline patient and disease characteristics of >27,000 women with endometriosis enrolled in the VIPOS study (Abstract) publication-title: Fertil Steril – volume: 27 start-page: 193 issue: 3 year: 2007 end-page: 210 ident: CR38 article-title: The global burden of headache: a documentation of headache prevalence and disability worldwide publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2007.01288.x – volume: 89 start-page: 538 issue: 3 year: 2008 end-page: 545 ident: CR5 article-title: Differences in characteristics among 1,000 women with endometriosis based on extent of disease publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2007.03.069 – ident: CR9 – volume: 28 start-page: 170 issue: 2 year: 2019 end-page: 177 ident: CR29 article-title: Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study publication-title: J Women's Health (Larchmt) doi: 10.1089/jwh.2018.7084 – volume: 29 start-page: 383 issue: 5 year: 2011 end-page: 390 ident: CR31 article-title: The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding publication-title: Semin Reprod Med doi: 10.1055/s-0031-1287662 – volume: 22 start-page: 83 issue: 2 year: 2014 end-page: 94 ident: CR43 article-title: Factors affecting the development of adverse drug reactions (review article) publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2013.02.003 – volume: 67 start-page: 817 issue: 5 year: 1997 end-page: 821 ident: CR30 article-title: Revised American Society for Reproductive Medicine classification of endometriosis: 1996 publication-title: Fertil Steril doi: 10.1016/S0015-0282(97)81391-X – volume: 10 start-page: 45 issue: 1 year: 2017 ident: CR44 article-title: Sex hormone allergy: clinical aspects, causes and therapeutic strategies - update and secondary publication publication-title: World Allergy Organ J doi: 10.1186/s40413-017-0176-x – volume: 118 start-page: 292 issue: 3 year: 2011 end-page: 298 ident: CR18 article-title: Complications after surgery for deeply infiltrating pelvic endometriosis publication-title: BJOG. doi: 10.1111/j.1471-0528.2010.02774.x – volume: 115 start-page: 1382 issue: 11 year: 2008 end-page: 1391 ident: CR6 article-title: Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--part 1 publication-title: BJOG. doi: 10.1111/j.1471-0528.2008.01878.x – volume: 285 start-page: 167 issue: 1 year: 2012 end-page: 173 ident: CR27 article-title: Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-011-1941-7 – volume: 19 start-page: 625 issue: 6 year: 2013 end-page: 639 ident: CR7 article-title: The social and psychological impact of endometriosis on women's lives: a critical narrative review publication-title: Hum Reprod Update doi: 10.1093/humupd/dmt027 – volume: 110 start-page: e392 issue: 4 year: 2018 ident: 94_CR36 publication-title: Fertil Steril – volume: 108 start-page: 21 issue: 1 year: 2010 ident: 94_CR24 publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2009.08.020 – volume: 2 start-page: CD002122 year: 2000 ident: 94_CR19 publication-title: Cochrane Database Syst Rev – volume: 74 start-page: 594 issue: 4 year: 2006 ident: 94_CR2 publication-title: Am Fam Physician – volume: 27 start-page: 148 issue: 2 year: 2018 ident: 94_CR28 publication-title: J Women's Health (Larchmt) doi: 10.1089/jwh.2017.6399 – ident: 94_CR9 doi: 10.3389/fsurg.2014.00024 – volume: 10 start-page: 45 issue: 1 year: 2017 ident: 94_CR44 publication-title: World Allergy Organ J doi: 10.1186/s40413-017-0176-x – volume: 82 start-page: 878 issue: 4 year: 2004 ident: 94_CR16 publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2004.03.046 – ident: 94_CR14 – volume: 73 start-page: 222 issue: 2 year: 2008 ident: 94_CR22 publication-title: Steroids. doi: 10.1016/j.steroids.2007.10.003 – volume: 43 start-page: 215 issue: 4 year: 2016 ident: 94_CR42 publication-title: Clin Exp Reprod Med doi: 10.5653/cerm.2016.43.4.215 – volume: 60 start-page: 477 issue: 3 year: 2017 ident: 94_CR13 publication-title: Clin Obstet Gynecol doi: 10.1097/GRF.0000000000000291 – volume: 25 start-page: 633 issue: 3 year: 2010 ident: 94_CR26 publication-title: Hum Reprod doi: 10.1093/humrep/dep469 – volume: 22 start-page: 83 issue: 2 year: 2014 ident: 94_CR43 publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2013.02.003 – volume: 82 start-page: 453 issue: 5 year: 2017 ident: 94_CR10 publication-title: Gynecol Obstet Investig doi: 10.1159/000452660 – volume: 8 start-page: 138 year: 2010 ident: 94_CR32 publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-8-138 – volume: 87 start-page: 1277 issue: 6 year: 2007 ident: 94_CR3 publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2006.11.051 – volume: 118 start-page: 292 issue: 3 year: 2011 ident: 94_CR18 publication-title: BJOG. doi: 10.1111/j.1471-0528.2010.02774.x – volume: 8 start-page: 204 issue: 3 year: 2012 ident: 94_CR37 publication-title: J Clin Neurol doi: 10.3988/jcn.2012.8.3.204 – volume: 20 start-page: 2698 issue: 10 year: 2005 ident: 94_CR1 publication-title: Hum Reprod doi: 10.1093/humrep/dei135 – volume: 89 start-page: 538 issue: 3 year: 2008 ident: 94_CR5 publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2007.03.069 – volume: 27 start-page: 193 issue: 3 year: 2007 ident: 94_CR38 publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2007.01288.x – volume: 29 start-page: 383 issue: 5 year: 2011 ident: 94_CR31 publication-title: Semin Reprod Med doi: 10.1055/s-0031-1287662 – volume: 285 start-page: 167 issue: 1 year: 2012 ident: 94_CR27 publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-011-1941-7 – volume: 29 start-page: 400 issue: 3 year: 2014 ident: 94_CR8 publication-title: Hum Reprod doi: 10.1093/humrep/det457 – volume: 15 start-page: 441 issue: 4 year: 2009 ident: 94_CR17 publication-title: Hum Reprod Update doi: 10.1093/humupd/dmp007 – volume: 7 start-page: 393 year: 2015 ident: 94_CR23 publication-title: Int J Women's Health doi: 10.2147/IJWH.S77202 – volume: 67 start-page: 817 issue: 5 year: 1997 ident: 94_CR30 publication-title: Fertil Steril doi: 10.1016/S0015-0282(97)81391-X – volume: 22 start-page: 951 issue: 6 year: 2015 ident: 94_CR33 publication-title: J Minim Invasive Gynecol doi: 10.1016/j.jmig.2015.04.017 – volume: 125 start-page: 55 issue: 1 year: 2018 ident: 94_CR12 publication-title: BJOG. doi: 10.1111/1471-0528.14711 – volume: 19 start-page: 123 issue: 2 year: 2018 ident: 94_CR39 publication-title: Expert Opin Pharmacother doi: 10.1080/14656566.2017.1414182 – ident: 94_CR35 – volume: 4 start-page: 9 issue: 1 year: 2018 ident: 94_CR4 publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-018-0008-5 – volume: 31 start-page: 517 year: 1995 ident: 94_CR21 publication-title: Drugs Today – volume: 151 start-page: 193 issue: 2 year: 2010 ident: 94_CR25 publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2010.04.002 – volume: 2 start-page: CD000346 year: 2007 ident: 94_CR20 publication-title: Cochrane Database Syst Rev – start-page: 218 volume-title: ECDEU Assessment Manual for Psychopharmacology (028 clinical global impressions [CGI]) year: 1976 ident: 94_CR34 – volume: 32 start-page: S1 issue: 7 Suppl 2 year: 2010 ident: 94_CR15 publication-title: J Obstet Gynaecol Can doi: 10.1016/S1701-2163(16)34589-3 – volume: 6 start-page: 34 issue: 1 year: 2017 ident: 94_CR11 publication-title: Curr Obstet Gynecol Rep doi: 10.1007/s13669-017-0187-1 – volume: 98 start-page: 104S issue: 1A year: 1995 ident: 94_CR41 publication-title: Am J Med doi: 10.1016/S0002-9343(99)80067-9 – volume: 19 start-page: 625 issue: 6 year: 2013 ident: 94_CR7 publication-title: Hum Reprod Update doi: 10.1093/humupd/dmt027 – volume: 28 start-page: 170 issue: 2 year: 2019 ident: 94_CR29 publication-title: J Women's Health (Larchmt) doi: 10.1089/jwh.2018.7084 – volume: 87 start-page: 49 issue: 1 year: 2016 ident: 94_CR40 publication-title: Neurology. doi: 10.1212/WNL.0000000000002798 – volume: 115 start-page: 1382 issue: 11 year: 2008 ident: 94_CR6 publication-title: BJOG. doi: 10.1111/j.1471-0528.2008.01878.x |
| SSID | ssj0054928 |
| Score | 2.3755603 |
| Snippet | Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 905 |
| SubjectTerms | Adult Embryology Endometriosis - complications Endometriosis - drug therapy Female Hormone Antagonists - therapeutic use Humans Medicine Medicine & Public Health Middle Aged Nandrolone - analogs & derivatives Nandrolone - therapeutic use Obstetrics/Perinatology/Midwifery Original Article Pain - complications Pain - prevention & control Prospective Studies Reproductive Medicine Treatment Outcome |
| Title | Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study |
| URI | https://link.springer.com/article/10.1007/s43032-019-00094-5 https://www.ncbi.nlm.nih.gov/pubmed/32052358 https://www.proquest.com/docview/2354735594 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FVEK8IO6EmxaJSqDiyN6LL7yloVUVaEE0hb5Z6_WaRAUbNekDfBQfwW_wM8xefAmBivJiRauJLXvOzs7OnJlF6EmomIwywjzFs9xj0tdTiidewSULhZ_HvmmStH8Q7h2xyTE_7vV-dlhLZ8tsKL_9sa7kf7QKY6BXXSV7Ac02N4UB-A36hStoGK7_pONDUWjGpY592y7EtekCD_AlzNlKJ4-0D_l-vhBgUDfHZHO0owMBmlw4bTjmml1Y5tVnfbpWtZgvbLn6a00S15UEdTUmGI8ZeOuGe7iSDQYv3jaO1UJuTTXR3Oms0qyffOuNOLG9DHQp2LATfhjPKpv2mJ8cqqqhe7yrZrZmxPvQ8gTeOl73pCo_zqp2fKIcr_jVVzBdLsDtIhmwbW2oXCuRzN9ioW04rmOmE0q9KLDnfA1VZ4z4vGvbbd8Bh2HaMdSJk7NrfmJLSteWE8sgWTBY5zWBJfEME9Pj7eLZUBqb9s9GOAXh1Ain_BLaIBE4dn20Mdrd3j6oHQXdGy-2pAf7Mq6my1R2rj1y1W9a2wytJfKNfzS9hq66jQ0eWZReRz1V3kCX9x114yY6tWDFgAa8AlZcFbgBK37qoPrj-zMMIMUNSLXYCkhf4BE2EMUdiGILUWwgegsd7e5Mx3ueO_DDk5RFS4-rmPpCBkL5OYl5Bt5TKIRgYcIzKSmPZJCHfhwRlsHawUQkZRGGhPiJLwKqFL2N-mVVqrsIs0wFAS1ykvkBizg4XQo-eAzeeSxiVdABCurPmUrXDV8fyvIp_bsiB2ir-c8X2wvmXOnHtZZSMNk6DydKBbMuJdQc-M0TNkB3rPqa-1Gi8zQ8HqDntT5TZ3EW5zzs3sXE76Mr7QR8gPrL0zP1EJzrZfbIgfQXwx7ISA |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Effectiveness+of+Dienogest+%28Visanne%C2%AE%29+for+Treatment+of+Endometriosis%3A+A+Large+Prospective+Cohort+Study&rft.jtitle=Reproductive+sciences+%28Thousand+Oaks%2C+Calif.%29&rft.au=Cho%2C+BaikSeol&rft.au=Roh%2C+Ju-Won&rft.au=Park%2C+Jonghoon&rft.au=Jeong%2C+Kyungah&rft.date=2020-03-01&rft.pub=Springer+International+Publishing&rft.issn=1933-7191&rft.eissn=1933-7205&rft.volume=27&rft.issue=3&rft.spage=905&rft.epage=915&rft_id=info:doi/10.1007%2Fs43032-019-00094-5&rft.externalDocID=10_1007_s43032_019_00094_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1933-7191&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1933-7191&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1933-7191&client=summon |